Cogent Biosciences, Inc. — Director's Dealing 2019

Mar 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Unum Therapeutics Inc. (UMRX)
CIK: 0001622229
Period of Report: 2019-03-25

Reporting Person: Ettenberg Seth (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-25	Common Stock	M	11485	$0.18	Acquired	11485	Direct
2019-03-25	Common Stock	S	11485	$4.1214	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-25	Stock Option (Right to Buy)	$0.18	A	11485	Acquired	2025-01-28	Common Stock (11485)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.39, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.